Journal of Comparative Effectiveness Research

Papers
(The H4-Index of Journal of Comparative Effectiveness Research is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more151
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis43
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary41
Engaging veterans in the research process: a practical guide31
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis29
Journal of Comparative Effectiveness Research : 2022 year in review25
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database23
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis22
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea22
An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain21
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis20
Corrigendum20
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy20
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis19
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies19
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study17
Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults17
0.1400899887085